Body mass index evolution and ovarian function in adolescent girls who received GnRH agonist treatment for central precocious puberty or early and fast puberty.
anti-Müllerian hormone
early and fast puberty
gonadotropin-releasing hormone agonist
polycystic ovary syndrome
precocious puberty
Journal
Journal of pediatric endocrinology & metabolism : JPEM
ISSN: 2191-0251
Titre abrégé: J Pediatr Endocrinol Metab
Pays: Germany
ID NLM: 9508900
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
16
05
2023
accepted:
05
09
2023
medline:
14
11
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
epublish
Résumé
Gonadotropin-releasing hormone agonist (GnRHa) has been used for central precocious puberty (CPP) or early and fast puberty. It was aimed to assess changes in body mass index (BMI), polycystic ovary syndrome (PCOS) frequency, and anti-Müllerian hormone (AMH) in girls who had been treated with GnRHa. Fifty-eight adolescent girls treated with GnRHa for CPP or early and fast puberty (3.75 mg/28 days), between 2011 and 2015, were re-evaluated in 2020-2022 at least 2 years after menstruation. Hormonal analyses were compared with 51 healthy adolescents. In the GnRHa-treated group, a statistically significant increase was observed when the BMI standard deviation score (SDS) at the beginning of the treatment was compared with the BMI SDS at the end of the treatment (p=0.038). A statistically significant decrease was observed when the BMI SDS at the end of the treatment was compared with the BMI SDS in late adolescence (p=0.012). When the BMI SDS at the beginning of the treatment was compared with the BMI SDS in late adolescence, it was observed that there was no statistically significant difference (p=0.196). Of the 58 girls in the GnRHa-treated group, 8 (14 %) had PCOS. Serum AMH levels did not differ between the GnRHa-treated and the control group. GnRHa treatment causes no adverse effect on BMI, at least in late adolescence. Girls treated with GnRHa were not found to be prone to developing PCOS. AMH levels were similar in the GnRHa-treated group as in the control group.
Identifiants
pubmed: 37735929
pii: jpem-2023-0232
doi: 10.1515/jpem-2023-0232
doi:
Substances chimiques
Gonadotropin-Releasing Hormone
33515-09-2
Peptide Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1044-1051Informations de copyright
© 2023 Walter de Gruyter GmbH, Berlin/Boston.
Références
Cheuiche, AV, da Silveira, LG, de Paula, LCP, Lucena, IRS, Silveiro, SP. Diagnosis and management of precocious sexual maturation: an updated review. Eur J Pediatr 2021;180:3073–87. https://doi.org/10.1007/s00431-021-04022-1 .
doi: 10.1007/s00431-021-04022-1
Carel, JC, Léger, J. Clinical practice. Precocious puberty. N Engl J Med 2008;358:2366–77. https://doi.org/10.1056/nejmcp0800459 .
doi: 10.1056/nejmcp0800459
Muir, A. Precocious puberty. Pediatr Rev 2006;27:373–81. https://doi.org/10.1542/pir.27.10.373 .
doi: 10.1542/pir.27.10.373
Teilmann, G, Pedersen, CB, Jensen, TK, Skakkebaek, NE, Juul, A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics 2005;116:1323–8. https://doi.org/10.1542/peds.2005-0012 .
doi: 10.1542/peds.2005-0012
Kaplowitz, P, Bloch, C, Sills, IN, Casella, SJ, Gonzalez, JL, Lynch, JL, et al.. Evaluation and referral of children with signs of early puberty. Pediatrics 2016;137:e20153732. https://doi.org/10.1542/peds.2015-3732 .
doi: 10.1542/peds.2015-3732
Wheeler, MD. Physical changes of puberty. Endocrinol Metab Clin N Am 1991;20:1–14. https://doi.org/10.1016/s0889-8529(18)30279-2 .
doi: 10.1016/s0889-8529(18)30279-2
Tao, Y, Si, C, Li, H, Han, J, Hou, H, Yang, M. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty. Ann Palliat Med 2020;9:53–62. https://doi.org/10.21037/apm.2020.01.04 .
doi: 10.21037/apm.2020.01.04
Guaraldi, F, Beccuti, G, Gori, D, Ghizzoni, L. Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 2016;174:R79–87. https://doi.org/10.1530/eje-15-0590 .
doi: 10.1530/eje-15-0590
Knific, T, Lazarevič, M, Žibert, J, Obolnar, N, Aleksovska, N, Šuput Omladič, J, et al.. Final adult height in children with central precocious puberty – a retrospective study. Front Endocrinol (Lausanne) 2022;13:1008474. https://doi.org/10.3389/fendo.2022.1008474 .
doi: 10.3389/fendo.2022.1008474
Magiakou, MA, Manousaki, D, Papadaki, M, Hadjidakis, D, Levidou, G, Vakaki, M, et al.. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109–17. https://doi.org/10.1210/jc.2009-0793 .
doi: 10.1210/jc.2009-0793
Satitpatanapan, P, Jaruratanasirikul, S, Sriplung, H. Menstrual cycle, reproductive function, body mass index, and metabolic profiles of women with former central precocious puberty: 10–20-year longitudinal cohort study in southern Thailand. J Pediatr Endocrinol Metab 2020;33:933–40. https://doi.org/10.1515/jpem-2020-0019 .
doi: 10.1515/jpem-2020-0019
Faienza, MF, Brunetti, G, Acquafredda, A, Delvecchio, M, Lonero, A, Gaeta, A, et al.. Metabolic outcomes, bone health, and risk of polycystic ovary syndrome in girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogues. Horm Res Paediatr 2017;87:162–9. https://doi.org/10.1159/000456546 .
doi: 10.1159/000456546
Franceschi, R, Gaudino, R, Marcolongo, A, Gallo, MC, Rossi, L, Antoniazzi, F, et al.. Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty. Fertil Steril 2010;93:1185–91. https://doi.org/10.1016/j.fertnstert.2008.11.016 .
doi: 10.1016/j.fertnstert.2008.11.016
Hagen, CP, Sørensen, K, Anderson, RA, Juul, A. Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril 2012;98:1326–30. https://doi.org/10.1016/j.fertnstert.2012.07.1118 .
doi: 10.1016/j.fertnstert.2012.07.1118
Nam, HK, Kim, HR, Rhie, YJ, Lee, KH. Serum anti-Müllerian hormone levels in precocious puberty girls according to stage of GnRH agonist treatment. J Kor Med Sci 2017;32:475–9. https://doi.org/10.3346/jkms.2017.32.3.475 .
doi: 10.3346/jkms.2017.32.3.475
Fu, J, Zhang, J, Chen, R, Ma, X, Wang, C, Chen, L, et al.. Long-term outcomes of treatments for central precocious puberty or early and fast puberty in Chinese girls. J Clin Endocrinol Metab 2020;105:705–15. https://doi.org/10.1210/clinem/dgz027 .
doi: 10.1210/clinem/dgz027
Lazar, L, Kauli, R, Pertzelan, A, Phillip, M. Gonadotropin-suppressive therapy in girls with early and fast puberty affects the pace of puberty but not total pubertal growth or final height. J Clin Endocrinol Metab 2002;87:2090–4. https://doi.org/10.1210/jcem.87.5.8481 .
doi: 10.1210/jcem.87.5.8481
Marshall, WA, Tanner, JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291–303. https://doi.org/10.1136/adc.44.235.291 .
doi: 10.1136/adc.44.235.291
Rosenfield, RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015;136:1154–65. https://doi.org/10.1542/peds.2015-1430 .
doi: 10.1542/peds.2015-1430
Teede, HJ, Misso, ML, Costello, MF, Dokras, A, Laven, J, Moran, L, et al.. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018;110:364–79. https://doi.org/10.1016/j.fertnstert.2018.05.004 .
doi: 10.1016/j.fertnstert.2018.05.004
Peña, AS, Witchel, SF, Hoeger, KM, Oberfield, SE, Vogiatzi, MG, Misso, M, et al.. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med 2020;18:72. https://doi.org/10.1186/s12916-020-01516-x .
doi: 10.1186/s12916-020-01516-x
Ibáñez, L, Oberfield, SE, Witchel, S, Auchus, RJ, Chang, RJ, Codner, E, et al.. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017;88:371–95. https://doi.org/10.1159/000479371 .
doi: 10.1159/000479371
De Sanctis, V, Soliman, AT, Di Maio, S, Soliman, N, Elsedfy, H. Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature. Acta Biomed 2019;90:345–59. https://doi.org/10.23750/abm.v90i3.8736 .
doi: 10.23750/abm.v90i3.8736
Pasquino, AM, Pucarelli, I, Accardo, F, Demiraj, V, Segni, M, Di Nardo, R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190–5. https://doi.org/10.1210/jc.2007-1216 .
doi: 10.1210/jc.2007-1216
Palmert, MR, Mansfield, MJ, Crowley, WFJr., Crigler, JFJr., Crawford, JD, Boepple, PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480–8. https://doi.org/10.1210/jc.84.12.4480 .
doi: 10.1210/jc.84.12.4480
Lazar, L, Lebenthal, Y, Yackobovitch-Gavan, M, Shalitin, S, de Vries, L, Phillip, M, et al.. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab 2015;100:1445–51. https://doi.org/10.1210/jc.2014-3748 .
doi: 10.1210/jc.2014-3748
Traggiai, C, Perucchin, PP, Zerbini, K, Gastaldi, R, De Biasio, P, Lorini, R. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 2005;153:463–4. https://doi.org/10.1530/eje.1.01975 .
doi: 10.1530/eje.1.01975
Anık, A, Çatlı, G, Abacı, A, Böber, E. Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty. Indian J Endocrinol Metab 2015;19:267–71. https://doi.org/10.4103/2230-8210.131770 .
doi: 10.4103/2230-8210.131770
Arrigo, T, De Luca, F, Antoniazzi, F, Galluzzi, F, Segni, M, Rosano, M, et al.. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533–7. https://doi.org/10.1530/eje.0.1500533 .
doi: 10.1530/eje.0.1500533
Chiavaroli, V, Liberati, M, D’Antonio, F, Masuccio, F, Capanna, R, Verrotti, A, et al.. GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with increased risk of polycystic ovary syndrome. Eur J Endocrinol 2010;163:55–62. https://doi.org/10.1530/eje-09-1102 .
doi: 10.1530/eje-09-1102
Luo, X, Liang, Y, Hou, L, Wu, W, Ying, Y, Ye, F. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2021;94:786–96. https://doi.org/10.1111/cen.14410 .
doi: 10.1111/cen.14410
Witchel, SF, Oberfield, SE, Peña, AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc 2019;3:1545–73. https://doi.org/10.1210/js.2019-00078 .
doi: 10.1210/js.2019-00078
Escobar-Morreale, HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018;14:270–84. https://doi.org/10.1038/nrendo.2018.24 .
doi: 10.1038/nrendo.2018.24
Yildiz, BO, Bozdag, G, Yapici, Z, Esinler, I, Yarali, H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012;27:3067–73. https://doi.org/10.1093/humrep/des232 .
doi: 10.1093/humrep/des232
Christensen, SB, Black, MH, Smith, N, Martinez, MM, Jacobsen, SJ, Porter, AH, et al.. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril 2013;100:470–7. https://doi.org/10.1016/j.fertnstert.2013.04.001 .
doi: 10.1016/j.fertnstert.2013.04.001
Heger, S, Partsch, CJ, Sippell, WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583–90. https://doi.org/10.1210/jc.84.12.4583 .
doi: 10.1210/jc.84.12.4583
Karavani, G, Chill, HH, Schachter-Safrai, N, Lomnitz, G, Gillis, D, Bauman, D. Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study. Clin Diabetes Endocrinol 2021;7:14. https://doi.org/10.1186/s40842-021-00129-4 .
doi: 10.1186/s40842-021-00129-4